Difficulties and Perspectives of Immunomodulatory Therapy with Mistletoe Lectins and Standardized Mistletoe Extracts in Evidence-based Medicine

Overview

Journal Evid Based Complement Alternat Med

Specialty Rehabilitation Medicine

Date 2009 Nov 27

PMID 19939951

Citations 10

Authors

Tibor Hajto

Krisztina Fodor

Pal Perjesi

Peter Nemeth

Affiliations

Soon will be listed here.

Abstract

Viscum album preparations are aqueous mistletoe plant extracts used in complementary and alternative medicine as immunomodulators in cancer therapy. However, evidence of immunological efficacy of mistletoe extracts (MEs) used in clinical trials is often lacking. Mechanisms involved in anti-tumor properties of ME and mistletoe lectins (MLs) modify both innate and adaptive immune systems, according to animal model experiments. In the background of these effects, a selective binding of ML on CD75 ganglioside receptors of interleukin 12 (IL-12)-producing macrophages or dendritic cells can play an important role. Immunological effects of ME correlate with their lectin activity, showing a bell-shaped dose-response curve of efficacy. Therefore, a correct determination of MLs for the standardization of commercial ME is essential. However, plant MLs exhibit heterogeneity, which most likely results from post-translational processing. In addition, amino acid analysis of ML has revealed numerous conservative substitutions along their amino acid sequence. Consequently, ML research needs new perspectives, and the advantages and disadvantages of purified and biologically better defined ML preparations are also discussed in this article.

Citing Articles

From inflammation to immune regulation: The dual nature of dietary lectins in health and disease.

Konozy E, Osman M Heliyon. 2024; 10(20):e39471.

PMID: 39502251 PMC: 11535980. DOI: 10.1016/j.heliyon.2024.e39471.

Receptor Heterodimerization and Co-Receptor Engagement in TLR2 Activation Induced by MIC1 and MIC4 from .

Mendonca-Natividade F, Lopes C, Ricci-Azevedo R, Sardinha-Silva A, Pinzan C, Alegre-Maller A Int J Mol Sci. 2019; 20(20).

PMID: 31658592 PMC: 6829480. DOI: 10.3390/ijms20205001.

Mistletoe-Based Drugs Work in Synergy with Radio-Chemotherapy in the Treatment of Glioma and in Glioblastoma Bearing Mice.

Schotterl S, Miemietz J, Ilina E, Wirsik N, Ehrlich I, Gall A Evid Based Complement Alternat Med. 2019; 2019:1376140.

PMID: 31354846 PMC: 6636536. DOI: 10.1155/2019/1376140.

Safety of Combined Treatment With Monoclonal Antibodies and Viscum album L Preparations.

Schad F, Axtner J, Kroz M, Matthes H, Steele M Integr Cancer Ther. 2018; 17(1):41-51.

PMID: 29444603 PMC: 5950938. DOI: 10.1177/1534735416681641.

Synergistic Antitumour Properties of in Alveolar Rhabdomyosarcoma.

Stammer R, Kleinsimon S, Rolff J, Jager S, Eggert A, Seifert G J Immunol Res. 2017; 2017:4874280.

PMID: 28791312 PMC: 5534308. DOI: 10.1155/2017/4874280.

References

Muthing J, Meisen I, Bulau P, Langer M, Witthohn K, Lentzen H . Mistletoe lectin I is a sialic acid-specific lectin with strict preference to gangliosides and glycoproteins with terminal Neu5Ac alpha 2-6Gal beta 1-4GlcNAc residues. Biochemistry. 2004; 43(11):2996-3007. DOI: 10.1021/bi0301892. View

Nagtegaal I, Marijnen C, Kranenbarg E, Mulder-Stapel A, Hermans J, van de Velde C . Local and distant recurrences in rectal cancer patients are predicted by the nonspecific immune response; specific immune response has only a systemic effect--a histopathological and immunohistochemical study. BMC Cancer. 2001; 1:7. PMC: 35356. DOI: 10.1186/1471-2407-1-7. View

Baskic D, Acimovic L, Samardzic G, Vujanovic N, Arsenijevic N . Blood monocytes and tumor-associated macrophages in human cancer: differences in activation levels. Neoplasma. 2001; 48(3):169-74. View

Savoie A, Lavastre V, Pelletier M, Hajto T, Hostanska K, Girard D . Activation of human neutrophils by the plant lectin Viscum album agglutinin-I: modulation of de novo protein synthesis and evidence that caspases are involved in induction of apoptosis. J Leukoc Biol. 2000; 68(6):845-53. View

Hajto T, Hostanska K, Frei K, Rordorf C, Gabius H . Increased secretion of tumor necrosis factors alpha, interleukin 1, and interleukin 6 by human mononuclear cells exposed to beta-galactoside-specific lectin from clinically applied mistletoe extract. Cancer Res. 1990; 50(11):3322-6. View

Simon L, Prebay D, Beretz A, Bagot J, Lobstein A, Rubinstein I . [Complementary and alternative medicines taken by cancer patients]. Bull Cancer. 2007; 94(5):483-8. View

Soler M, Stoeva S, Voelter W . Complete amino acid sequence of the B chain of mistletoe lectin I. Biochem Biophys Res Commun. 1998; 246(3):596-601. DOI: 10.1006/bbrc.1998.8670. View

Terabe M, Berzofsky J . The role of NKT cells in tumor immunity. Adv Cancer Res. 2008; 101:277-348. PMC: 2693255. DOI: 10.1016/S0065-230X(08)00408-9. View

Fischer S, Scheffler A, Kabelitz D . Oligoclonal in vitro response of CD4 T cells to vesicles of mistletoe extracts in mistletoe-treated cancer patients. Cancer Immunol Immunother. 1997; 44(3):150-6. PMC: 11037688. DOI: 10.1007/s002620050367. View

10.

Kawashima I, Yoshida Y, Taya C, Shitara H, Yonekawa H, Karasuyama H . Expansion of natural killer cells in mice transgenic for IgM antibody to ganglioside GD2: demonstration of prolonged survival after challenge with syngeneic tumor cells. Int J Oncol. 2003; 23(2):381-8. View

11.

Hajto T, Krisztina F, Ildiko A, Zsolt P, Peter B, Peter N . Unexpected different binding of mistletoe lectins from plant extracts to immobilized lactose and N-acetylgalactosamine. Anal Chem Insights. 2009; 2:43-50. PMC: 2716816. View

12.

Ostrand-Rosenberg S, Sinha P . Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol. 2009; 182(8):4499-506. PMC: 2810498. DOI: 10.4049/jimmunol.0802740. View

13.

Urech K, Scher J, Hostanska K, Becker H . Apoptosis inducing activity of viscin, a lipophilic extract from Viscum album L. J Pharm Pharmacol. 2005; 57(1):101-9. DOI: 10.1211/0022357055083. View

14.

Murray J . How the MHC selects Th1/Th2 immunity. Immunol Today. 1998; 19(4):157-63. DOI: 10.1016/s0167-5699(97)01237-1. View

15.

Hajto T, Hostanska K, Berki T, Palinkas L, Boldizsar F, Nemeth P . Oncopharmacological Perspectives of a Plant Lectin (Viscum album Agglutinin-I): Overview of Recent Results from In vitro Experiments and In vivo Animal Models, and Their Possible Relevance for Clinical Applications. Evid Based Complement Alternat Med. 2005; 2(1):59-67. PMC: 1062151. DOI: 10.1093/ecam/neh058. View

16.

Tabiasco J, Pont F, Fournie J, Vercellone A . Mistletoe viscotoxins increase natural killer cell-mediated cytotoxicity. Eur J Biochem. 2002; 269(10):2591-600. DOI: 10.1046/j.1432-1033.2002.02932.x. View

17.

Hajto T, Hostanska K, Gabius H . Modulatory potency of the beta-galactoside-specific lectin from mistletoe extract (Iscador) on the host defense system in vivo in rabbits and patients. Cancer Res. 1989; 49(17):4803-8. View

18.

Harmsma M, Gromme M, Ummelen M, Dignef W, Tusenius K, Ramaekers F . Differential effects of Viscum album extract IscadorQu on cell cycle progression and apoptosis in cancer cells. Int J Oncol. 2004; 25(6):1521-9. View

19.

Muthing J, Burg M, Mockel B, Langer M, Metelmann-Strupat W, Werner A . Preferential binding of the anticancer drug rViscumin (recombinant mistletoe lectin) to terminally alpha2-6-sialylated neolacto-series gangliosides. Glycobiology. 2002; 12(8):485-97. DOI: 10.1093/glycob/cwf062. View

20.

Chaudhuri D, Suriano R, Mittelman A, Tiwari R . Targeting the immune system in cancer. Curr Pharm Biotechnol. 2009; 10(2):166-84. DOI: 10.2174/138920109787315114. View